GitLab Inc., together with its subsidiaries, develops software for the software development lifecycle in the United States, Europe, and the Asia Pacific.
FAIL · Does not pass the screen
56.28 USD
Price as of 23 Oct 2026Daily close, not a live quoteLast reviewed 5 days ago
Screened 2026-10-23 · the tape above runs as of 18:04 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
Price56.28 USD at the 23 Oct 2026 close
Ethical screenDoes not pass
OptionsOpen interest leans heavily to calls (put/call 0.34)
Last reviewed23 Oct 2026 (5 days ago)
A summary of the dated readings below, not a live quote and not advice.
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 56.28 against the desk's fair-value range, base estimate 39.39, over the last year.
Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.34, read 2026-10-23
Ethical does not pass the values gate
Price56.28 USD
Fair value39.39
Ethical score70.0/100
Our investment reviews on this name
2026-10-02Read Accumulation49.95+12.7% to today ✓Markup gives way to Accumulation after a 20% rise in 5 weeks
2026-08-29Read Markup41.66+35.1% to today ✓Accumulation gives way to Markup after a 7% rise in 4 days
2026-08-25Read Accumulation38.97+44.4% to today ✓Markup gives way to Accumulation after a 40% rise in 8 weeks
2026-07-02Read Markup27.79+102.5% to today ✓First review on file: Markup
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
GitLab Inc. holds its Accumulation at $56.28. The statistical read favours the buyers, held for 15 days.
As held on the ledger · 2026-10-23
Phase
Accumulation
Quantitative state
The statistical read favours the buyers, held for 15 days
Price at the screen
$56.28
Valuation
N/A trailing · 52.97 forward price to earnings
Values screen
FAIL· score 70.0
Beta
0.99
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
0.01%
Below 33%
Interest-bearing debt is just 0.0% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
59.81%
Below 33%
Interest-bearing cash and securities are 59.8% of assets, above the one-third limit.
Fail
Receivables
30.99%
Below 49%
Money owed to the company is 31.0% of assets, under the 49% limit.
Pass
Revenue purity
4.78%
Below 5%
Only 4.8% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
GitLab's business is fine, but its cash and interest-bearing securities are about 60% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-27. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when GTLB's ethical verdict changes
Today GTLB does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
Fair value range in USD, drawn from the 2026-10-23 screen. The gold marker is the market price at the same screen. The price runs 28.4% above the base estimate.
Third-party analyst targets: 24 covering, consensus Buy. The average target sits −2% from the screen price.
Reading the gap · Both our model and the Street see limited upside at this price.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
GitLab Platform Wins Fans But Not Value
Picture a single workbench where coders, security teams and ops staff all reach for the same tools without switching tabs. GitLab built that workbench, and revenue keeps rising at 23 percent a year. Yet the shares sit 13 percent above our fair value, carry a forward multiple of 31.8 times, and still lose money on a negative 2 percent margin. We pass.
The market already prices in perfection, with twenty-three analysts clustered around a hold rating and a $32 target that matches the current price. Negative return on equity and an unknown moat leave little room for disappointment. Ethical screens are cleared, but that alone does not justify stretching for growth at any price.
Valuation risk sits front and centre. If growth slows or losses persist, the premium can compress quickly. Currency moves and competition from larger cloud suites add further pressure on margins that have yet to turn positive. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
GTLB trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-25Accumulation$55.00+5.9%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 5.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it A. Technically it is momentum reading bullish. Over the past year the shares are down 42%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (23 analysts) rates it hold, with a mean price target of $30. Insiders have been net buyers over the past quarter.
2026-10-18Accumulation$51.95+4.0%Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 4.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 42%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (23 analysts) rates it hold, with a mean price target of $30. Insiders have been net buyers over the past quarter.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 19.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 42%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (23 analysts) rates it hold, with a mean price target of $30. Insiders have been net buyers over the past quarter.
2026-09-01Markup$41.66+0.0%Entry 12
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 42%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (23 analysts) rates it hold, with a mean price target of $30. Insiders have been net buyers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-31Markup$41.66+0.0%Entry 11
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 42%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (23 analysts) rates it hold, with a mean price target of $30. Insiders have been net buyers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-30Markup$41.66+0.0%Entry 10
Our analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 42%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (23 analysts) rates it hold, with a mean price target of $30. Insiders have been net buyers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-29Markup · changed$41.66+0.0%Entry 9
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 42%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (23 analysts) rates it hold, with a mean price target of $30. Insiders have been net buyers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-28Accumulation$41.66+0.0%Entry 8
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 42%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (23 analysts) rates it hold, with a mean price target of $30. Insiders have been net buyers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-27Accumulation$41.66+0.0%Entry 7
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 42%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (23 analysts) rates it hold, with a mean price target of $30. Insiders have been net buyers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
2026-08-26Accumulation$41.66+6.9%Entry 6
Our analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 6.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B. Technically it is sitting below its long-term trend line with momentum reading neutral. Over the past year the shares are down 42%. Our forward projection puts the odds of a 10% gain over the next month near 22%. The street (23 analysts) rates it hold, with a mean price target of $30. Insiders have been net buyers over the past quarter. It reported earnings in this window, a natural checkpoint for the thesis.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
